GAUT8 (Galacturonosyltransferase 8) belongs to the CAZy GT8 family and is involved in synthesizing homogalacturonan (HG), a major pectin component. Key findings include:
Role in Cell Wall Integrity: GAUT8 is essential for cell adhesion and wall integrity, as gaut8 mutants exhibit reduced galacturonic acid (GalA) levels (25% reduction in leaves) and dwarfism .
Enzymatic Function: Biochemical studies confirm GAUT8 as a galacturonosyltransferase (GalAT), catalyzing the transfer of GalA residues to growing HG chains .
Though not explicitly detailed in the provided sources, antibodies targeting GAUT homologs (e.g., GAUT1) have been used in related studies. For example:
Immunoprecipitation: GAUT1 antibodies immunodepleted GalAT activity in Arabidopsis extracts, confirming its role in HG synthesis . Similar methodologies could theoretically apply to GAUT8.
Mutant Analysis: gaut8 mutants (e.g., qua1) show pleiotropic effects, including cell wall defects, which are often characterized using antibodies against cell wall components .
Data from gaut8 mutants highlight its functional importance:
Studies on GAUT8 leverage techniques applicable to antibody-based research:
Immunoassays: GAUT1 antiserum was used to immunoprecipitate GalAT activity, a method transferable to GAUT8 studies .
Cell Wall Profiling: Monosaccharide composition analysis (e.g., HPAEC-PAD) and glycome profiling are critical for assessing GAUT8’s impact on pectin structure .
Based on the provided search results, there is no available data specifically addressing GAUT8 antibodies. The materials extensively cover GAUT10-related research in plant cell wall biosynthesis , α-Gal antibodies , and diabetes-associated GAD/ZnT8 autoantibodies , but do not mention GAUT8. This discrepancy suggests either a nomenclature error (e.g., GAUT8 vs. GAUT10) or that GAUT8 antibodies represent an emerging research area not yet reflected in indexed literature.
Below are scientifically structured FAQs based on the closest related antibody research domains from the provided materials:
Conflicting results between monoclonal antibodies (e.g., 27H8 vs. BSI-B4) require:
The ZnT8/GAD65 chimeric protein assay demonstrates:
Epitope engineering: Fusion of immunodominant regions (ZnT8₃₂₋₃₆₉ + GAD₅₅₀₋₅₈₅) preserves conformational epitopes .
Platform comparison:
Clinical validation: Requires cohort studies comparing onset timelines in LADA vs. T1D patients .
Critical controls include: